Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by Nisa Investment Advisors LLC

Nisa Investment Advisors LLC decreased its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 37.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,348 shares of the biopharmaceutical company’s stock after selling 4,335 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $533,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of the company. Meeder Asset Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 332.9% during the 1st quarter. Meeder Asset Management Inc. now owns 342 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 263 shares during the last quarter. Quadrant Capital Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 543.2% during the 1st quarter. Quadrant Capital Group LLC now owns 521 shares of the biopharmaceutical company’s stock valued at $46,000 after buying an additional 440 shares during the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $47,000. Northwestern Mutual Wealth Management Co. raised its stake in shares of Alnylam Pharmaceuticals by 268.9% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 701 shares of the biopharmaceutical company’s stock valued at $66,000 after buying an additional 511 shares during the last quarter. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of Alnylam Pharmaceuticals by 76.9% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,060 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 1,330 shares during the last quarter. 89.71% of the stock is owned by hedge funds and other institutional investors.

Shares of Alnylam Pharmaceuticals stock traded down $1.24 on Monday, hitting $72.74. The company’s stock had a trading volume of 3,547 shares, compared to its average volume of 692,766. The company has a quick ratio of 9.12, a current ratio of 9.33 and a debt-to-equity ratio of 0.20. Alnylam Pharmaceuticals, Inc. has a 1 year low of $60.27 and a 1 year high of $124.21. The firm has a market cap of $7.88 billion, a P/E ratio of -9.49 and a beta of 2.46. The firm’s fifty day moving average is $73.43.

In related news, CEO John Maraganore sold 49,457 shares of Alnylam Pharmaceuticals stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $70.00, for a total value of $3,461,990.00. Following the sale, the chief executive officer now directly owns 239,450 shares in the company, valued at approximately $16,761,500. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 3.60% of the company’s stock.

ALNY has been the subject of a number of recent research reports. Goldman Sachs Group reiterated a “neutral” rating and set a $80.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, May 23rd. Stifel Nicolaus lifted their price objective on Alnylam Pharmaceuticals from $110.00 to $116.00 and gave the company a “buy” rating in a research note on Monday, April 15th. Zacks Investment Research lowered Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, May 8th. ValuEngine upgraded Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday. Finally, Leerink Swann lifted their price objective on Alnylam Pharmaceuticals to $90.00 and gave the company a “market perform” rating in a research note on Tuesday, April 9th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and a consensus target price of $127.44.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.

Read More: Candlestick

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).

Institutional Ownership by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.